One pill to prevent HIV and pregnancy? new study tests simpler option for women
NCT ID NCT07288190
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a single daily pill that combines HIV prevention (PrEP) and birth control is easier for women to take consistently than taking two separate pills. About 300 women without HIV will try both approaches in a crossover design, and researchers will measure adherence through blood tests. The goal is to see if a simpler regimen improves daily use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- DPP (single pill combining FTC/TDF and ethinyl estradiol/levonorgestrel)
- What this could lead to
- If it works, this could make it simpler for women to prevent both HIV and pregnancy with just one daily pill.
- What could go wrong
- This is a small, early-phase study (Phase 2) with only 300 participants, so results may not apply to everyone. It focuses on adherence, not on actual HIV or pregnancy prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 to 39 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 16 through 39 years old (inclusive) at Screening. * Adults must be able and willing to provide informed consent. Adolescents (16- and 17-year-olds) will be consented according to applicable local guidelines, by obtaining participant assent and where applicable parental or guardian permission. * Able and willing to provide adequate locator information. * Able and willing to comply with all study procedures. * Must be post-menarche and pre-menopausal and could potentially become pregnant. * Sexually active, defined as having had penile-vaginal sex within the 3 months before Screening (per self-report) * Negative pregnancy test at Screening and Enrollment. * Does not intend to become pregnant within the next 12 months. * Willing to use COCs for at least 48 weeks as their method of contraception. * HIV negative at Screening and Enrollment. * Willing to use oral PrEP for at least 48 weeks. * Hepatitis B (HBV) surface antigen (HbsAg) negative per blood test at Screening. * Hepatitis C (HCV) negative at Screening. * Normal estimated creatinine clearance (eCrCl) ≥ 60 ml/min per blood test at Screening. Exclusion Criteria: * Intolerance, adverse reaction, or laboratory abnormality associated with PrEP use in the past. * Unable to become pregnant e.g., had a tubal ligation or hysterectomy or otherwise lacks a uterus, or is currently using another form of contraception. * Medically ineligible for combined hormonal contraception and specifically COCs per World Health Organization (WHO) medical eligibility criteria for contraceptive use or similar local medical eligibility guidelines (e.g., Centers for Disease Control and Prevention eligibility criteria). * Medically ineligible for PrEP based on WHO and/or local guidelines. * Using or planning to use another pregnancy prevention product other than oral contraception (condoms are permitted) during the next 48 weeks. * Using or planning to use another HIV prevention product other than condoms during the next 48 weeks. * Any other condition the clinician feels would jeopardize the health and wellbeing of the participant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Eswatini Prevention Center CRS
Mbabane, Eswatini
-
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
Kampala, Uganda
-
Spilhaus CRS
Harare, Zimbabwe
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Session couples program cut drug use and HIV risk?
- How much lidocaine reaches a newborn during an urgent C-Section?
- Decades of HIV data could reveal which treatments last
- Can testing together again keep male couples HIV-Free?
- Can a rapid HIV test get people treated sooner?
- Can Same-Day HIV prevention reach people before infection takes hold?